{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:07:50Z","timestamp":1792782470962,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Otto-von-Guericke-Universit\u00e4t Magdeburg","id":[{"id":"https:\/\/ror.org\/00ggpsq73","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and purpose<\/jats:title>\n                    <jats:p>\n                      Combined chemoradiotherapy is a\u00a0key treatment strategy for esophageal cancer in both neoadjuvant and definitive settings. Accurate and consistent target volume delineation is essential to optimize therapeutic efficacy and minimize toxicity.\n                      <jats:sup>18<\/jats:sup>\n                      F-fluorodeoxyglucose (\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG) positron emission tomography\/computed tomography (PET\/CT) enables visualization of metabolically active tumor regions and may improve the accuracy and reproducibility of target volume definition. This retrospective study aimed to evaluate the impact of PET\/CT-guided contouring on target volume size, target volume geometry, organ-at-risk exposure, and interobserver variability compared with conventional CT-based delineation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Twenty patients treated between 2022 and 2024 at the Department of Radiation Oncology, University Hospital Magdeburg, were included. Gross tumor volumes (GTVs) were independently delineated on CT and PET\/CT datasets. Clinical target volumes (CTVs) and planning target volumes (PTVs) were subsequently generated. Geometric agreement was assessed using the Dice similarity coefficient (DSC) and 95th\u00a0percentile Hausdorff distance (HD95). Interobserver variability was evaluated using simultaneous truth  and performance level estimation (STAPLE)-generated reference contours. Paired t\u2011tests (\u03b1\u202f=\u20090.05) were used to assess volumetric and dosimetric differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      PET\/CT-based planning significantly reduced PTV volumes, with mean PTV decreasing from 602.3\u202f\u00b1\u2009267.4\u202fcm\n                      <jats:sup>3<\/jats:sup>\n                      to 453.2\u202f\u00b1\u2009237.4\u202fcm\n                      <jats:sup>3<\/jats:sup>\n                      (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&lt;\u20090.001). In four patients (20%), more than 100\u202fcm\n                      <jats:sup>3<\/jats:sup>\n                      of the PET-defined target volume was located outside the original CT-based PTV, indicating clinically relevant geometric modification of irradiation fields. Eight patients (40%) showed HD95 values exceeding 25\u202fmm between CT- and PET\/CT-based target volumes. PET\/CT-based planning also reduced pulmonary radiation exposure, with lung V20 decreasing from 10.39\u202f\u00b1\u20091.23% to 7.85\u202f\u00b1\u20091.18% (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.001) and lung V30 from 4.41\u202f\u00b1\u20090.76% to 2.46\u202f\u00b1\u20090.37% (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.003). No significant reduction in cardiac or left anterior descending coronary artery (LAD) exposure was observed. Interobserver analysis demonstrated comparable overall agreement between CT- and PET\/CT-based contouring, with lower HD95 variability for PET\/CT-based delineation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PET\/CT-guided radiotherapy planning substantially influences target volume geometry in esophageal cancer and enables identification of metabolically active disease not adequately covered by CT-based planning alone. In addition to significant target volume reduction and lower pulmonary dose exposure, PET\/CT-based contouring may support more consistent target volume delineation. Prospective studies are warranted to determine whether these geometric and dosimetric advantages translate into improved oncologic outcomes and reduced treatment-related toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00066-026-02605-1","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:20:55Z","timestamp":1790259655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of PET\/CT imaging on target volume delineation and radiotherapy planning in patients with locally advanced esophageal cancer"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1390-1727","authenticated-orcid":false,"given":"Vera","family":"Ashykhmina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpad","family":"Dezs\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Glowka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Lushchaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Riethmueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislav","family":"Tchaikovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Medenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"3","key":"2605_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray\u00a0F, Laversanne\u00a0M, Sung\u00a0H, Ferlay\u00a0J, Siegel\u00a0RL, Soerjomataram\u00a0I et\u00a0al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"2605_CR2","volume-title":"Cancer in Germany 2019\/2020: relative 5-year survival rates for esophageal cancer","author":"Centre for Cancer Registry Data at the Robert Koch Institute","year":"2023","unstructured":"Centre for Cancer Registry Data at the Robert Koch Institute (2023) Cancer in Germany 2019\/2020: relative 5\u2011year survival rates for esophageal cancer, 14th\u00a0edn. Robert Koch Institute, Berlin (Available from: https:\/\/www.krebsdaten.de (Accessed May 25, 2026))","edition":"14"},{"key":"2605_CR3","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Esophageal and Esophagogastric Junction Cancers. Version 2.2026. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/esophageal.pdf (accessed Mai 2026)."},{"key":"2605_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-025-00871-3","volume":"25","author":"B Peng","year":"2025","unstructured":"Peng\u00a0B, Sun\u00a0H, Hou\u00a0J, Zhang\u00a0Y, Zhao\u00a0H, Chen\u00a0Z et\u00a0al (2025) PET\/MRI is superior to PET\/CT in detecting oesophago and gastric carcinomas: a\u00a0meta-analysis. Cancer Imaging 25:50. https:\/\/doi.org\/10.1186\/s40644-025-00871-3","journal-title":"Cancer Imaging"},{"key":"2605_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12880-025-01565-9","volume":"25","author":"A Mohebbi","year":"2025","unstructured":"Mohebbi\u00a0A, Mohammadzadeh\u00a0S, Moradi\u00a0Z, Mohammadi\u00a0A, Poustchi\u00a0H, Tavangar\u00a0SM et\u00a0al (2025) Staging of esophageal cancer using PET\/MRI: a\u00a0systematic review with head-to-head comparison. BMC Med Imaging 25:32. https:\/\/doi.org\/10.1186\/s12880-025-01565-9","journal-title":"BMC Med Imaging"},{"issue":"10","key":"2605_CR6","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","volume":"33","author":"R Obermannov\u00e1","year":"2022","unstructured":"Obermannov\u00e1\u00a0R, Alsina\u00a0M, Cervantes\u00a0A, Leong\u00a0T, Lordick\u00a0F, Nilsson\u00a0M et\u00a0al (2022) Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33(10):992\u20131004. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.003 (PubMed PMID: 35914638)","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"4","key":"2605_CR7","doi-asserted-by":"publisher","first-page":"580","DOI":"10.2478\/raon-2024-0043","volume":"58","author":"A Secerov-Ermenc","year":"2024","unstructured":"Secerov-Ermenc\u00a0A, Peterlin\u00a0P, Velenik\u00a0V, Jeromen-Peressutti\u00a0A, But-Hadzic\u00a0J, Anderluh\u00a0F, Segedin\u00a0B (2024) Inter-observer variation in gross tumour volume delineation of oesophageal squamous cell carcinoma on MR, CT and PET\/CT. Radiol Oncol 58(4):580\u2013587. https:\/\/doi.org\/10.2478\/raon-2024-0043","journal-title":"Radiol Oncol"},{"issue":"22","key":"2605_CR8","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen\u00a0P, Hulshof\u00a0MCCM, van Lanschot\u00a0JJB, Steyerberg\u00a0EW, van Berge Henegouwen\u00a0MI, Wijnhoven\u00a0BPL et\u00a0al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074\u20132084","journal-title":"N Engl J Med"},{"issue":"3","key":"2605_CR9","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.radonc.2017.01.008","volume":"122","author":"F Duane","year":"2017","unstructured":"Duane\u00a0F, Aznar\u00a0MC, Bartlett\u00a0F, Cutter\u00a0DJ, Darby\u00a0SC, Jagsi\u00a0R et\u00a0al (2017) A cardiac contouring atlas for radiotherapy. Clin Transl Radiat Oncol 122(3):416\u2013422. https:\/\/doi.org\/10.1016\/j.radonc.2017.01.008 (PMID: 28233564; PMCID: PMC5356506)","journal-title":"Radiother Oncol"},{"key":"2605_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13014-017-0916-7","volume":"12","author":"L Wills","year":"2017","unstructured":"Wills\u00a0L, Maggs\u00a0R, Lewis\u00a0G et\u00a0al (2017) Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy. Radiat Oncol 12:179\u2013179. https:\/\/doi.org\/10.1186\/s13014-017-0916-7","journal-title":"Radiation Oncology"},{"key":"2605_CR11","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2025","unstructured":"R Core Team (2025) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria"},{"issue":"9","key":"2605_CR12","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","volume":"30","author":"A Fedorov","year":"2012","unstructured":"Fedorov\u00a0A, Beichel\u00a0R, Kalpathy-Cramer\u00a0J, Finet\u00a0J, Fillion-Robin\u00a0JC, Pujol\u00a0S, Bauer\u00a0C et\u00a0al (2012) 3D Slicer as an Image Computing Platform for the Quantitative Imaging Network. Magn Reson Imaging 30(9):1323\u20131341. https:\/\/doi.org\/10.1016\/j.mri.2012.05.001","journal-title":"Magn Reson Imaging"},{"issue":"10","key":"2605_CR13","doi-asserted-by":"publisher","DOI":"10.1118\/1.4754659","volume":"39","author":"C Pinter","year":"2012","unstructured":"Pinter\u00a0C, Lasso\u00a0A, Wang\u00a0A, Jaffray\u00a0D, Fichtinger\u00a0G (2012) SlicerRT: Radiation therapy research toolkit for 3D Slicer. Med Phys 39(10):6332. https:\/\/doi.org\/10.1118\/1.4754659","journal-title":"Med Phys"},{"issue":"2","key":"2605_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.carj.2014.08.006","volume":"66","author":"H Tirumani","year":"2015","unstructured":"Tirumani\u00a0H, Rosenthal\u00a0MH, Tirumani\u00a0SH, Shinagare\u00a0AB, Krajewski\u00a0KM, Ramaiya\u00a0NH (2015) Esophageal Carcinoma: Current Concepts in the Role of Imaging in Staging and Management. Canadian Association of Radiologists Journal 66(2):130\u2013139. https:\/\/doi.org\/10.1016\/j.carj.2014.08.006","journal-title":"Canadian Association of Radiologists Journal"},{"issue":"4","key":"2605_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4253\/wjge.v14.i4.205","volume":"14","author":"M Radlinski","year":"2022","unstructured":"Radlinski\u00a0M, Shami\u00a0VM (2022) Role of endoscopic ultrasound in esophageal cancer. World J Gastrointest Endosc 14(4):205\u2013214. https:\/\/doi.org\/10.4253\/wjge.v14.i4.205","journal-title":"World J Gastrointest Endosc"},{"issue":"10","key":"2605_CR16","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3748\/wjg.14.1479","volume":"14","author":"SR Puli","year":"2008","unstructured":"Puli\u00a0SR, Reddy\u00a0JB, Bechtold\u00a0ML, Antillon\u00a0D, Ibdah\u00a0JA, Antillon\u00a0MR (2008) Staging accuracy of esophageal cancer by endoscopic ultrasound: a\u00a0meta-analysis and systematic review. World J Gastroenterol 14(10):1479\u20131490. https:\/\/doi.org\/10.3748\/wjg.14.1479","journal-title":"World J Gastroenterol"},{"issue":"7","key":"2605_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158373","volume":"11","author":"LN Luo","year":"2016","unstructured":"Luo\u00a0LN, He\u00a0LJ, Gao\u00a0XY, Huang\u00a0XX, Shan\u00a0HB, Luo\u00a0GY et\u00a0al (2016) Endoscopic ultrasound for preoperative esophageal squamous cell carcinoma: a meta-analysis. PLoS One 11(7):e0158373. https:\/\/doi.org\/10.1371\/journal.pone.0158373","journal-title":"PLoS One"},{"issue":"8","key":"2605_CR18","doi-asserted-by":"publisher","first-page":"693.e1","DOI":"10.1016\/j.crad.2017.02.022","volume":"72","author":"KG Foley","year":"2017","unstructured":"Foley\u00a0KG, Christian\u00a0A, Fielding\u00a0P, Lewis\u00a0WG, Roberts\u00a0SA (2017) Accuracy of contemporary oesophageal cancer lymph node staging with radiological-pathological correlation. Clin Radiol 72(8):693.e1\u2013693.e7. https:\/\/doi.org\/10.1016\/j.crad.2017.02.022","journal-title":"Clin Radiol"},{"issue":"3","key":"2605_CR19","first-page":"377","volume":"235","author":"W Schr\u00f6der","year":"2002","unstructured":"Schr\u00f6der\u00a0W, Baldus\u00a0SE, M\u00f6nig\u00a0SP et\u00a0al (2002) Lymph node staging of esophageal squamous cell carcinoma in patients with and without neoadjuvant radiochemotherapy: Histomorphologic analysis. Ann Surg 235(3):377\u2013385","journal-title":"Ann Surg"},{"issue":"10","key":"2605_CR20","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1111\/j.1440-1746.2009.05927.x","volume":"24","author":"K Takizawa","year":"2009","unstructured":"Takizawa\u00a0K, Matsuda\u00a0T, Kozu\u00a0T, Eguchi\u00a0T, Kato\u00a0H, Nakanishi\u00a0Y, Hijikata\u00a0A, Saito\u00a0D (2009) Lymph node staging in esophageal squamous cell carcinoma: a\u00a0comparative study of endoscopic ultrasonography versus computed tomography. J\u00a0Gastroenterol Hepatol 24(10):1687\u20131691. https:\/\/doi.org\/10.1111\/j.1440-1746.2009.05927.x","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"2605_CR21","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/cncr.10330","volume":"94","author":"H Kato","year":"2002","unstructured":"Kato\u00a0H, Kuwano\u00a0H, Nakajima\u00a0M, Miyazaki\u00a0T, Yoshikawa\u00a0M, Ojima\u00a0H, Tsukada\u00a0K, Oriuchi\u00a0N, Inoue\u00a0T, Endo\u00a0K (2002) Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 94(4):921\u2013928 (PMID: 11920459)","journal-title":"Cancer"},{"issue":"3","key":"2605_CR22","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s00259-008-0959-y","volume":"36","author":"BE Chatterton","year":"2009","unstructured":"Chatterton\u00a0BE, Ho Shon\u00a0I, Baldey\u00a0A, Lenzo\u00a0N, Patrikeos\u00a0A, Kelley\u00a0B, Wong\u00a0D, Ramshaw\u00a0JE, Scott\u00a0AM (2009) Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging 36(3):354\u2013361. https:\/\/doi.org\/10.1007\/s00259-008-0959-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2605_CR23","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s11307-010-0306-0","volume":"13","author":"AJ Walker","year":"2011","unstructured":"Walker\u00a0AJ, Spier\u00a0BJ, Perlman\u00a0SB, Stangl\u00a0JR, Frick\u00a0TJ, Gopal\u00a0DV, Lindstrom\u00a0MJ, Weigel\u00a0TL, Pfau\u00a0PR (2011) Integrated PET\/CT fusion imaging and endoscopic ultrasound in the pre-operative staging and evaluation of esophageal cancer. Mol Imaging Biol 13(1):166\u2013171. https:\/\/doi.org\/10.1007\/s11307-010-0306-0","journal-title":"Mol Imaging Biol"},{"key":"2605_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2021.109524","volume":"136","author":"CP Reinert","year":"2021","unstructured":"Reinert\u00a0CP, Sekler\u00a0J, Gani\u00a0C, Nikolaou\u00a0K, la Foug\u00e8re\u00a0C, Pfannenberg\u00a0C, Gatidis\u00a0S (2021) Impact of PET\/CT on management of patients with esophageal cancer - results from a\u00a0PET\/CT registry study. Eur J Radiol 136:109524. https:\/\/doi.org\/10.1016\/j.ejrad.2021.109524","journal-title":"Eur J Radiol"},{"issue":"3","key":"2605_CR25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.radonc.2009.12.043","volume":"94","author":"CT Muijs","year":"2010","unstructured":"Muijs\u00a0CT, Beukema\u00a0JC, Pruim\u00a0J, Mul\u00a0VEM, Groen\u00a0HJM, Plukker\u00a0JTM et\u00a0al (2010) FDG-PET\/CT imaging for target volume delineation in esophageal cancer. Clin Transl Radiat Oncol 94(3):284\u2013290. https:\/\/doi.org\/10.1016\/j.radonc.2009.12.043","journal-title":"Radiother Oncol"},{"key":"2605_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.critrevonc.2016.08.015","volume":"107","author":"J Lu","year":"2016","unstructured":"Lu\u00a0J, Sun\u00a0XD, Yang\u00a0X, Tang\u00a0XY, Qin\u00a0Q, Zhu\u00a0HC, Cheng\u00a0HY, Sun\u00a0XC (2016) Impact of PET\/CT on radiation treatment in patients with esophageal cancer: a\u00a0systematic review. Crit Rev Oncol Hematol 107:128\u2013137. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.08.015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"2605_CR27","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2967\/jnumed.116.182543","volume":"58","author":"SP Ng","year":"2017","unstructured":"Ng\u00a0SP, Gomez\u00a0DR, Wang\u00a0X, Shroff\u00a0GS, Liao\u00a0Z, Hong\u00a0DS et\u00a0al (2017) FDG PET\/CT impacts on target volume delineation and management of esophageal cancer patients receiving radiation therapy. J\u00a0Nucl Med 58(4):639\u2013645. https:\/\/doi.org\/10.2967\/jnumed.116.182543","journal-title":"J Nucl Med"},{"issue":"3","key":"2605_CR28","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.radonc.2006.03.004","volume":"78","author":"T Leong","year":"2006","unstructured":"Leong\u00a0T, Everitt\u00a0C, Yuen\u00a0K, Condron\u00a0S, Hui\u00a0A, Ngan\u00a0SY et\u00a0al (2006) A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy planning for oesophageal cancer. Clin Transl Radiat Oncol 78(3):254\u2013261. https:\/\/doi.org\/10.1016\/j.radonc.2006.03.004","journal-title":"Radiother Oncol"},{"issue":"1","key":"2605_CR29","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.ijrobp.2010.09.020","volume":"82","author":"J Welsh","year":"2012","unstructured":"Welsh\u00a0J, Palmer\u00a0MB, Ajani\u00a0JA, Liao\u00a0Z, Swisher\u00a0SG, Hoffe\u00a0SE et\u00a0al (2012) Esophageal cancer dose escalation using a simultaneous integrated boost technique. Adv Radiat Oncol 82(1):468\u2013474. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.09.020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2605_CR30","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.crad.2016.11.004","volume":"72","author":"AF Scarsbrook","year":"2017","unstructured":"Scarsbrook\u00a0AF, Barrington\u00a0SF, Townsend\u00a0CE, McGowan\u00a0DR, Miles\u00a0K, Hogg\u00a0A et\u00a0al (2017) The role of FDG PET-CT in the management of esophageal and gastro-esophageal malignancy. Clin Radiol 72(6):432\u2013444. https:\/\/doi.org\/10.1016\/j.crad.2016.11.004","journal-title":"Clin Radiol"},{"issue":"10","key":"2605_CR31","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1200\/JCO.22.02036","volume":"41","author":"Y Chen","year":"2023","unstructured":"Chen\u00a0Y, Wang\u00a0X, Wang\u00a0Q, Li\u00a0Y, Wang\u00a0Z, Yang\u00a0Z et\u00a0al (2023) Comparing paclitaxel plus fluorouracil versus cisplatin plus fluorouracil in chemoradiotherapy for locally advanced esophageal squamous cell cancer: A randomized, multicenter, phase III clinical trial (ESO-Shanghai 1). J\u00a0Clin Oncol 41(10):1818\u20131828. https:\/\/doi.org\/10.1200\/JCO.22.02036","journal-title":"J Clin Oncol"},{"key":"2605_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.02.053","author":"H Zhu","year":"2021","unstructured":"Zhu\u00a0H, Rivin del Campo\u00a0E, Ye\u00a0J et\u00a0al (2021) Involved-field irradiation in definitive chemoradiotherapy for locoregional esophageal squamous cell carcinoma: Results from the ESO-Shanghai 1 trial. Adv Radiat Oncol. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.02.053","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"21","key":"2605_CR33","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1111\/1759-7714.14656","volume":"13","author":"J Lyu","year":"2022","unstructured":"Lyu\u00a0J, Yisikandaer\u00a0A, Li\u00a0T, Zhang\u00a0X, Wang\u00a0X, Tian\u00a0Z et\u00a0al (2022) Comparison between the effects of elective nodal irradiation and involved-field irradiation on long-term survival in thoracic esophageal squamous cell carcinoma patients: A prospective, multicenter, randomized, controlled study in China. Thorac Cancer 13(21):3012\u20133021. https:\/\/doi.org\/10.1111\/1759-7714.14656","journal-title":"Thorac Cancer"},{"key":"2605_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1323908","volume":"13","author":"Y Dai","year":"2023","unstructured":"Dai\u00a0Y, Wang\u00a0J, Chen\u00a0H, He\u00a0Y, Hu\u00a0C (2023) A\u00a0comparative study of elective nodal irradiation and involved field irradiation in elderly patients with advanced esophageal cancer. Front Oncol 13:1323908. https:\/\/doi.org\/10.3389\/fonc.2023.1323908","journal-title":"Front Oncol"},{"key":"2605_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1000161","volume":"12","author":"H Wang","year":"2022","unstructured":"Wang\u00a0H, Song\u00a0C, Zhao\u00a0X, Deng\u00a0W, Shen\u00a0W (2022) The role of involved field irradiation versus elective nodal irradiation in definitive radiotherapy or chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis. Front Oncol 12:1000161. https:\/\/doi.org\/10.3389\/fonc.2022.1000161","journal-title":"Front Oncol"},{"key":"2605_CR36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409408","author":"J Hoeppner","year":"2025","unstructured":"Hoeppner\u00a0J, Lordick\u00a0F, Brunner\u00a0T et\u00a0al (2025) Perioperative chemotherapy or neoadjuvant chemoradiotherapy for esophageal adenocarcinoma. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2409408","journal-title":"N Engl J Med"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02605-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-026-02605-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02605-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:20:59Z","timestamp":1790259659000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-026-02605-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":36,"alternative-id":["2605"],"URL":"https:\/\/doi.org\/10.1007\/s00066-026-02605-1","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"2 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by the Ethics Committee of Otto-von-Guericke University Magdeburg (approval no.\u00a028\/25) and was conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"V.\u00a0Ashykhmina, A.\u00a0Dezs\u00f6, A.\u00a0Glowka, T.\u00a0Lushchaeva, P.\u00a0Riethmueller, S.\u00a0Tchaikovski, and D.\u00a0Medenwald declare that they have no competing interests.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}